Crinetics Pharmaceuticals Inc. (CRNX)
Summary
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Tops Revenue Estimates
Crinetics Pharmaceuticals, Inc. (CRNX) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to a loss of $1.23 per share a year ago.
Why Crinetics Stock Soared 99% This Week
Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.
Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?
CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Crinetics Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 120 | $4,887.32 | $10,063.2 | $5,175.88 | 105.9% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1 | $37.42 | $84.46 | $47.04 | 125.71% |
 Farallon Capital Farallon Capital Management LLC | 8.99M | $400.41M | $761.38M | $360.97M | 90.15% |
| BG Bart Gancher Intech Investment Management LLC | 24,453 | $957,522.38 | $2.06M | $1.1M | 114.87% |
 John H. Burbank III Passport Capital LLC | 2.35M | $97.29M | $199.17M | $101.88M | 104.71% |
Crinetics Pharmaceuticals Inc. (CRNX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Crinetics Pharmaceuticals Inc. ever had a stock split?
Crinetics Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | R. Scott Struthers CEO | NASDAQ (NGS) Exchange | 22663K107 CUSIP |
| US Country | 594 Employees | - Last Dividend | - Last Split | 18 Jul 2018 IPO Date |
Overview
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is deeply engaged in the discovery, development, and eventual commercialization of innovative therapeutics targeting rare endocrine disorders and endocrine-related tumors. Founded in 2008, Crinetics has established its headquarters in the critical biotech hub of San Diego, California. The company leverages its expertise to address unmet medical needs in the endocrine field, focusing on conditions that are often overlooked but significantly impact patient quality of life.
Products and Services
- Paltusotine:
- CRN04894:
- PTH Receptor Antagonists:
- Orally Available Somatostatin Receptor Type 3 Targeted Nonpeptide Agonists:
- Thyroid-Stimulating Hormone Receptor Antagonists:
- Oral GLP-1 and GIP Nonpeptides:
An oral selective nonpeptide somatostatin receptor type 2 agonist, Paltusotine is Crinetics' flagship product candidate. It is currently undergoing a Phase 3 clinical trial for acromegaly, a hormonal disorder that results from an excess of growth hormone, and a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. This demonstrates the company's dedication to finding effective treatments for complex endocrine diseases.
This investigational oral nonpeptide product candidate aims to antagonize the adrenocorticotrophic hormone (ACTH) receptor. Having completed a Phase 1 study, CRN04894 is designed to treat diseases caused by excess ACTH, such as congenital adrenal hyperplasia and Cushing's disease, highlighting Crinetics' pursuit of solutions for adrenal gland disorders.
These compounds are being developed to target the parathyroid hormone (PTH) receptor, for the treatment of conditions such as primary hyperparathyroidism and humoral hypercalcemia of malignancy. By focusing on diseases of excess PTH, Crinetics aims to address the significant challenges faced by patients with these rare disorders.
Crinetics is researching these compounds for the potential treatment of autosomal dominant polycystic kidney disease, a genetic disorder affecting the kidneys. This reflects the company's commitment to exploring applications of its technology across a range of endocrine and related diseases.
Developed for the treatment of Graves' disease and thyroid eye disease, these antagonists target the thyroid-stimulating hormone receptor, addressing critical needs in managing thyroid health and associated conditions.
Targeting diabetes and obesity, these products represent Crinetics' expansion into metabolic disorders, utilizing its endocrine expertise to develop treatments that address widespread health issues beyond rare diseases.
